Enliven Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
ELVN Nasdaq 2836 www.enliventherapeutics.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Enliven Therapeutics, Inc.

Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update - Nov 13th, 2024 9:05 pm
Enliven Therapeutics to Present at the Jefferies London Healthcare Conference - Nov 7th, 2024 9:05 pm
Why this largely unknown company is one analyst's top biotech pick - Oct 18th, 2024 8:38 pm
Enliven Therapeutics’ ELVN-001 shows promise in Phase I CML trial - Sep 30th, 2024 8:52 am
Enliven Therapeutics Announces Positive Data Update from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - Sep 28th, 2024 1:35 pm
Here's Why Momentum in Enliven Therapeutics, Inc. (ELVN) Should Keep going - Sep 26th, 2024 12:50 pm
Enliven Therapeutics Announces Details Regarding the Presentation of Updated ELVN-001 Phase 1a Data at the ESH-iCMLf 26th Annual John Goldman Conference on CML - Sep 18th, 2024 8:05 pm
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst - Sep 9th, 2024 6:05 pm
Wall Street Analysts See a 58.78% Upside in Enliven Therapeutics, Inc. (ELVN): Can the Stock Really Move This High? - Sep 4th, 2024 1:55 pm
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans - Aug 24th, 2024 1:08 pm
Wall Street Analysts Think Enliven Therapeutics, Inc. (ELVN) Could Surge 43.04%: Read This Before Placing a Bet - Aug 16th, 2024 1:55 pm
Enliven Therapeutics Reports Second Quarter Financial Results and Provides a Business Update - Aug 13th, 2024 8:05 pm
Enliven Therapeutics to Present at Two Upcoming Investor Conferences - May 29th, 2024 8:05 pm
Enliven Therapeutics Reports First Quarter Financial Results and Provides a Business Update - May 14th, 2024 8:05 pm
Enliven Therapeutics Shares First Look At Safety, Clinical Activity Of Lead Program - Apr 11th, 2024 7:44 pm
Enliven Therapeutics Announces Positive Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 in Chronic Myeloid Leukemia - Apr 11th, 2024 11:55 am
Enliven Therapeutics Appoints Dr. Lori Kunkel to Board of Directors - Apr 9th, 2024 8:05 pm
Owning 36% shares,institutional owners seem interested in Enliven Therapeutics, Inc. (NASDAQ:ELVN), - Apr 9th, 2024 10:59 am
Enliven Therapeutics to Share Initial Proof of Concept Data from Phase 1 Clinical Trial of ELVN-001 and Host Virtual Key Opinion Leader Event on April 11, 2024 - Mar 28th, 2024 8:05 pm
Enliven Therapeutics Inc Director Rahul Ballal Sells 13,278 Shares - Mar 23rd, 2024 5:51 am